Abingworth — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
BoardIsaac Manke(Director)in
Board seatBali Muralidhar· per SEC Form D · $94.8M raise · filed Dec 2020
Co-investorsAccess BiotechnologyRiverVest Venture PartnersACORN BIOVENTURESBoulder VenturesNew Enterprise Associates (NEA)
Developing innovative biologic therapeutics with transformative clinical potential.
South San Francisco, US
Board seatKurt von Emster· per SEC Form D · $70.7M raise · filed Feb 2021
Co-investorsSofinnova VenturesKleiner Perkins
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Board seatAndrew Sinclair· per SEC Form D · $200.2M raise · filed Jul 2020
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatBali Muralidhar· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersFidelity InvestmentsIntermediate Capital Group+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.